Streetbeat News

Revenues

RXST

RxSight shares surged following the announcement of better-than-expected Q1 financial results and an upward revision of its FY24 revenue guidance, surpassing estimates. Additionally, the positive outlook was reinforced as multiple firms increased their price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:44 pm

BIOX

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) announced the approval of three new bio-insecticidal/bio-nematicidal solutions by Brazil's Ministry of Agriculture and Livestock. These solutions, derived from inactivated cells of the company's proprietary Burkholderia platform, mark a significant regulatory milestone in Brazil, the world's leading bio-control market. This approval enables the commercialization of these products in Brazil, potentially opening the door for future product launches. Bioceres' bio-control solutions are commercialized under the Rizobacter brand and other third-party brands in Brazil. The company's CEO, Federico Trucco, highlighted the approval as a key milestone for growth in Brazil and noted the global relevance of this market to the company.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:43 pm

CWD

Caliber (NASDAQ:CWD), a real estate investor, developer, and manager, announced the sale of a 50-acre parcel in Johnstown, Colorado, to the Archdiocese of Denver for $7.7 million. The land, part of a larger 190-acre purchase in June 2021, is intended for a new Catholic high school. This sale is part of Caliber's Johnstown Development, a 750-acre master-planned project. The development is expected to include multifamily, retail, and industrial spaces, aiming to boost the Northern Colorado area's growth and investment.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:41 pm

BLDP

Ballard Power Systems anticipates its 2024 revenue to be heavily weighted towards the second half of the year, mirroring its 2023 pattern, with about 30% expected in the first half and 70% in the latter half. The company has not provided specific revenue or net income guidance for 2024 due to the nascent stage of the hydrogen fuel cell market. Ballard's projected total operating expenses for 2024 are between $145 million and $165 million, with capital expenditures estimated to be between $50 million and $70 million.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:40 pm

CMND

DAVE

HIMS

Clearmind Medicine (CMND) shares surged 60% following an exclusive patent licensing agreement with Yissum Research Development Company. Hims & Hers Health (HIMS) shares rose 18% after reporting Q1 financial results that exceeded expectations and providing optimistic Q2 and FY24 revenue guidance. Dave (DAVE) shares increased 22% after announcing better-than-expected Q1 financial results and FY24 operating revenue forecast.

Portfolio Pulse from ryanfaloona@benzinga.com

May 07, 2024 | 12:36 pm

MYNA

RKLB

Mynaric has been chosen by Rocket Lab to provide optical terminals for the Space Development Agency's Tranche 2 Transport Layer - Beta Program, with the order valued at approximately $15M.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:25 pm

NBY

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) reports a record increase in ordered product sales of Avenova-branded products on Amazon.com for April 2024, with a more than 20% increase compared to April 2023. This marks consecutive record sales months for the company, attributed to its focused eyecare product line and enhanced marketing efforts. The U.S. dry eye disease treatment market, where Avenova is positioned, is projected to reach nearly $5 billion by 2030.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:19 pm

TACT

TransAct Technologies has revised its FY24 total net sales forecast downwards from $53M-$58M to $45M-$50M, below the estimated $54.143M. Additionally, the company anticipates its full year 2024 total adjusted EBITDA to range between negative $2.5 million and negative $3.5 million.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:13 pm

AWH

Aspira Women's Health Inc. (NASDAQ:AWH) announced the publication of two peer-reviewed manuscripts supporting the use of its OvaWatch diagnostic tool for ovarian cancer risk assessment in women with adnexal masses. The studies, published in Frontiers of Medicine and Gynecologic Oncology, demonstrate OvaWatch's potential to reduce unnecessary surgeries and provide effective risk monitoring, potentially accelerating its adoption for patient management. The company's total addressable market for its ovarian cancer risk assessment tests, OvaSuite, is estimated at 2.0-3.0 million tests per year.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:10 pm

TALK

Talkspace has reaffirmed its revenue forecast to be between $185M-$195M, aligning with the analyst estimate of $191.55M, and anticipates a growth rate of 23%-30%. Additionally, the company expects its adjusted EBITDA to be in the range of $4M-$8M.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:06 pm